Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
75 hedge funds and large institutions have $126M invested in Avadel Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 11 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
14% more call options, than puts
Call options by funds: $678K | Put options by funds: $594K
6% less funds holding
Funds holding: 80 → 75 (-5)
13.29% less ownership
Funds ownership: 64.7% → 51.4% (-13%)
33% less capital invested
Capital invested by funds: $189M → $126M (-$62.7M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.87M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$1.13M |
| 3 |
JP Morgan Chase
New York
|
+$953K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$907K |
| 5 |
BC
Broadfin Capital
New York
|
+$702K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$9.45M |
| 3 |
DM
Deerfield Management
New York
|
-$7.48M |
| 4 |
Morgan Stanley
New York
|
-$4.55M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
76
Endurant Capital Management
San Mateo,
California
| – | -$406K | -55,700 | Closed |
|
|
MYIA
77
Mount Yale Investment Advisors
Denver,
Colorado
| – | -$101K | -13,792 | Closed |
|
|
AG
78
Aperio Group
Sausalito,
California
| – | -$76K | -10,371 | Closed |
|
|
TRCT
79
Tower Research Capital (TRC)
New York
| – | -$71K | -9,740 | Closed |
|
80
Russell Investments Group
London,
United Kingdom
| – | -$37K | -5,052 | Closed |
|
|
PA
81
Parallel Advisors
San Francisco,
California
| – | -$5K | -697 | Closed |
|
82
Lazard Asset Management
New York
| – | -$4K | -600 | Closed |
|
83
Simplex Trading
Chicago,
Illinois
| – | -$1K | -251 | Closed |
|
|
JGIA
84
Jackson Grant Investment Advisers
Stamford,
Connecticut
| – | -$2K | -250 | Closed |
|
AVDL Hedge Fund Activity: Q2 2018 in Review
75 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2018, worth a combined $126M — down 33% from $189M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AVDL and 6 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 24 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.87M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.4M sold.
- 75 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2018, down from 80 in Q1 2018.
- Funds reported $126M of Avadel Pharmaceuticals stock for Q2 2018, down 33% quarter-over-quarter.
- 6 funds opened new Avadel Pharmaceuticals positions in Q2 2018 and 11 closed out, a net change of -5 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2018 was Renaissance Technologies, an estimated $1.87M added.
- The largest Avadel Pharmaceuticals seller in Q2 2018 was Armistice Capital, an estimated $13.4M sold.
Based on aggregated 13F filings for Q2 2018.